Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Mar;3(1):16-22.
doi: 10.5114/ceh.2017.65279. Epub 2017 Jan 20.

Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype

Dzmitry Danilau  1 , Dzmitry Litvinchuk  1 , Nikita Solovey  1 , Olga Krasko  2 , Igor Karpov  1
Affiliations

Association of TNF-α and CCL5 with response to interferon-based therapy in patients with HCV 1 genotype

Dzmitry Danilau et al. Clin Exp Hepatol. 2017 Mar.

Abstract

Aim of the study: To evaluate the role of potential genetic predictors -308G/A TNF-α and -403G/A CCL5 in treatment for HCV 1 genotype.

Material and methods: Treatment results of 130 patients with chronic hepatitis C 1 genotype according to different genotypes of IL28B, CCL5, and TNF-α were analysed using multiple logistic regression.

Results: IL28B genotypes CC/CT/TT were found in 27 (20.8%), 74 (56.9%), and 29 (22.3%) patients. Genotypes GG/GA/AA of -308G/A TNF-α were revealed in 98 (75.4%), 30 (23.1%), and 2 (1.5%) patients. Genotypes GG/GA/AA of -403G/A CCL5 were revealed in 86 (66.2%), 39 (30%), and 5 (3.8%) patients, respectively. The previously known effect of IL28B was observed. IL28B TT genotype decreased end of treatment response (EOTR) rates by a factor of 29.0 (95% CI: 6.4-183). The combination of CCL5 GG and IL28B CT genotypes increased the risk of failure to achieve EOTR by a factor of 28.5 (95% CI: 7.2-160). Genotypes GA and AA of TNF-α (-308) G/A SNP increased the risk of relapse in patients who achieved EOTR (OR = 9.4; 95% CI: 2.4-48).

Conclusions: Practitioners may benefit from using these predictors when considering indications for the antiviral therapy and deciding on the treatment regimen.

Keywords: CCL5; IL28B; SNP; TNF-α; peginterferon alfa.

PubMed Disclaimer

Conflict of interest statement

Authors report no conflict of interest.

Similar articles

See all similar articles

References

    1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77–87. - PMC - PubMed
    1. McCaughan GW. Fibrosis progression in chronic hepatitis C virus infection. Gut. 2004;53:318–321. - PMC - PubMed
    1. Lingala S, Ghany MG. Natural History of Hepatitis C. Gastroenterol Clin North Am. 2015;44:717–734. - PMC - PubMed
    1. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: A meta-analysis and meta-regression. Hepatology. 2008;48:418–431. - PubMed
    1. Curry MP. HIV and Hepatitis C Virus: Special Concerns for Patients with Cirrhosis. J Infect Dis. 2013;207(Suppl 1):S40–44. - PubMed